AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Vantage 2020 Preview: Strong Sales and Product Launches Set the Stage for Biopharma Growth, but Underlying Market Concerns Exist

December 19, 2019 GMT

LONDON & BOSTON & TOKYO--(BUSINESS WIRE)--Dec 19, 2019--

Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Vantage 2020 Preview, published today . Vaccines and diabetes also show strong growth, the latter despite heavy competition and pricing pressure. Vertex’s Trikafta – one of the mostly valuable R&D products of 2019 – will be a top performer as well.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005045/en/

Despite a strong outlook for many industry segments, biopharma investors have concerns about increasing market volatility next year. Although investors have seen time-to-exit by either M&A or IPO steadily decrease, in 2019 companies took bigger discounts to proposed valuations at IPO and private investors saw smaller returns on new flotations.

“Biopharma is poised for a strong finish in 2019, but many are wondering whether the current rally can be maintained for much longer,” said Amy Brown, report author. “Political and pricing uncertainty in the US could make stock market conditions tougher next year, which would make it much harder to float, and that could have knock-on effects to other sectors, like venture financing.”

Notable Report Findings:

This report is published by Vantage, the independent editorial team at Evaluate Ltd. All data cited is from EvaluatePharma Vision, the first single view of pharmaceutical risk and return. Download the full report at: https://www.evaluate.com/Pharma2020Preview.

About Evaluate Ltd.
Evaluate provides trusted commercial intelligence for the pharmaceutical industry and their advisors. Our EvaluatePharma Vision platform delivers complete and dynamic asset valuations alongside a seamless, comprehensive view of the global market outlook.

Vantage provides award-winning, thought-provoking news and insights into current and future developments in the industry.

Evaluate has been a partner to industry-leading organizations for over 20 years. For more information on how we radically transform our clients’ confidence in strategic portfolio decisions, visit www.evaluate.com.

Follow us on Twitter: @EvaluatePharma, @Vantageanalysis

View source version on businesswire.com:https://www.businesswire.com/news/home/20191219005045/en/

CONTACT: Evaluate Ltd.

Jennifer Dinkel

+1 (617) 936-7783

jennifer.dinkel@evaluate.com

KEYWORD: MASSACHUSETTS IRELAND UNITED STATES UNITED KINGDOM JAPAN NORTH AMERICA ASIA PACIFIC EUROPE

INDUSTRY KEYWORD: MEDICAL DEVICES MEDICAL SUPPLIES FINANCE DIABETES PROFESSIONAL SERVICES OTHER HEALTH BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Evaluate Ltd.

Copyright Business Wire 2019.

PUB: 12/19/2019 03:00 AM/DISC: 12/19/2019 03:00 AM

http://www.businesswire.com/news/home/20191219005045/en